Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
Open accessThe DOI matches its Crossref record; 311 of the 333 references it cites were found in a registry or an index; 70 of the 272 sources its claims cite were checked for support.
Abstract
Non-alcoholic fatty liver disease (NAFLD) represents the most common form of chronic liver disease worldwide. Due to its association with obesity and diabetes and the fall in hepatitis C virus morbidity, cirrhosis in NAFLD is becoming the most frequent indication to liver transplantation, but the pathogenetic mechanisms are still not completely understood. The so-called gut-liver axis has gained enormous interest when data showed that its alteration can lead to NAFLD development and might favor the occurrence of non-alcoholic steatohepatitis (NASH). Moreover, several therapeutic approaches targeting the gut-pancreas-liver axis, e.g., incretins, showed promising results in NASH treatment. In this review, we describe the role of incretin hormones in NAFLD/NASH pathogenesis and treatment and how metagenomic/metabolomic alterations in the gut microbiota can lead to NASH in the presence of gut barrier modifications favoring the passage of bacteria or bacterial products in the portal circulation, i.e., bacterial translocation.
Overview
CoChat Summary
TL;DR
This review argues that the gut-pancreas-liver axis—incretin hormones, gut microbiota, bile acid signaling, and intestinal permeability—contributes to NAFLD/NASH pathogenesis and offers therapeutic targets. It summarizes evidence that GLP-1 receptor agonists, FXR agonists, and microbiota/permeability-directed approaches have variable benefits, with many human data still limited.
Key findings
- NAFLD prevalence is estimated at about 25% in the general population, rising to 57% in those with BMI ≥30 kg/m², 70% in diabetic subjects, and 90% in morbidly obese patients undergoing metabolic surgery.
- In the LEAN trial, 52 biopsy-proven NASH patients were randomized 1:1 to liraglutide 1.8 mg daily or placebo for 48 weeks; NASH resolution occurred in 39% vs 9%, and fewer liraglutide-treated patients showed fibrosis progression (2/23 vs 8/22).
- In FLINT, obeticholic acid 25 mg/day for 72 weeks improved NAFLD activity score and decreased liver fibrosis, but NASH resolution occurred in only 22% of OCA patients without a statistically significant effect vs placebo; no effect was seen in advanced fibrosis, and pruritus developed in 23%. REGENERATE interim analysis at month 18 reported 23% (25 mg) and 18% (10 mg) vs 12% placebo meeting the primary endpoint of fibrosis improvement by at least one stage without NASH worsening.
- A meta-analysis by Dong et al. including six GLP-1RA studies found reduced NASH activity (steatosis, lobular inflammation, hepatocyte ballooning) and fibrosis stage vs placebo; however, conclusive human data on GLP-1RA effects on hepatic fibrosis are lacking. Intestinal permeability was demonstrated in only 39% of NAFLD patients and 49% of NASH patients.
Methods
- Narrative review; no primary data collection or systematic search is described. It synthesizes preclinical and clinical literature on incretins, DPP-4 inhibitors, GLP-1 co-agonists, gut microbiota, bile acids, and gut permeability in NAFLD/NASH.
- Evidence discussed includes mouse models (ob/ob, db/db, high-fat diet, methionine/choline-deficient diet, diet-induced obesity), human randomized trials (e.g., LEAN, FLINT, REGENERATE), meta-analyses, and mechanistic studies.
Limitations
- Stated: GLP-1RA studies often had limited patient numbers and lacked control groups; conclusive human data on GLP-1RA effects on hepatic fibrosis are lacking; no effective therapies directly targeting the gut-microbiota-liver axis exist; and there is no evidence that long-term gut bacterial composition change improves NAFLD/NASH in humans.
- Stated: intestinal permeability assessment lacks a unique gold standard, and only 39% of NAFLD and 49% of NASH patients demonstrated permeability.
- Evident: as a narrative review, it does not systematically appraise study quality or perform quantitative synthesis; conclusions rely heavily on animal models and small or heterogeneous human trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
46 Valid · 8 Not valid · 138 Not checked · 28 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“The epithelial barrier dysfunction may be triggered by the presence of some microbial communities and their derived metabolites [270,271], which can be assessed by circulating zonulin as well as by circulating LPS.”
§ Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH > 5. Gut Permeability
What the sources say
- Disputedcites [270] Scheppach, 1994, Effects of short chain fatty acids on gut morphology and function, Gut sourceExperimental — accuracy not yet measured
The section “Effects of SCFAs on mucus release and cellular differentiation” says that a lack of luminal nutrients may impair the gut barrier, rather than that the presence of microbial metabolites triggers dysfunction. The “SCFAs and colitis” section likewise describes inflammation associated with a lack of these bacterial fermentation products and improvement after SCFA treatment. The paper does not address whether other microbial communities or metabolites might have the effect claimed. (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [271] Wirth, R., Bodi, N., Maroti, G., Bagyanszki, M., Talapka, P., Fekete, E., Bagi, Z., and Kovacs, K.L. (2014). Regionally distinct alterations in the composition of the gut microbiota in rats with streptozotocin-induced diabetes. PLoS ONE, 9. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that mucosal inflammation produces a leaky epithelium and that the altered ileal microbiota, particularly Klebsiella, could be associated with that inflammation. It also says the direction of causation is unclear. The paper does not attribute epithelial barrier dysfunction to microbial-derived metabolites. (LLM, conf=0.84)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In humans, studies have provided evidence for a negative correlation between A. Muciniphila abundance and overweight, obesity, untreated T2D or hypertension.”
§ Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH > 6. Targeting the Gut Permeability to Improve NAFLD/NASH
What the sources say
- Not checked yetcites [312] Plovier, 2017, A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice, Nat. Med. source
- Disputedcites [313] Dao, 2016, Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: Relationship with gut microbiome richness and ecology, Gut sourceExperimental — accuracy not yet measured
The Results section (‘A. muciniphila is associated with a healthier metabolic status’; page unavailable) reports no difference in abundance between overweight and obese participants. The Introduction (page unavailable) describes human T2D findings as conflicting, including a study that found higher abundance in people with T2D. Although this paper links higher abundance to healthier metabolic measures, it does not establish the claimed negative correlations with the listed conditions. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
- Supportedcites [314] Depommier, 2019, Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: A proof-of-concept exploratory study, Nat. Med. source
The source paper’s Abstract explicitly states that human studies have found a negative correlation between A. muciniphila abundance and overweight, obesity, untreated T2DM, or hypertension. The claim closely paraphrases that statement. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The major effect of incretins is the potentiation of glucose-stimulated insulin secretion by pancreatic β-cells [14,15,16,17].”
§ Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH > 2. Physiological Effects of Incretin Hormones > 2.1. Incretin Secretion and Physiological Effects
What the sources say
- Not checked yetcites [14] Dupre, 1973, Stimulation of insulin secretion by gastric inhibitory polypeptide in man, J. Clin. Endocrinol. Metab. source
- Not checked yetcites [15] Kreymann, 1987, Glucagon-like peptide-1 7-36: A physiological incretin in man, Lancet source
- Not checked yetcites [16] Campbell, 2013, Pharmacology, physiology, and mechanisms of incretin hormone action, Cell Metab. source
- Partly supportedcites [17] Holst, 2006, Glucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005, Diabetologia sourceExperimental — accuracy not yet measured
The Discovery of glucagon-like peptide-1 section (p. 1) describes GIP as glucose-dependent and insulinotropic, and GLP-1 and diabetes treatment (p. 2) says GLP-1 stimulates glucose-induced insulin secretion. But the latter section also says GLP-1’s gastrointestinal effects may be its most important actions under physiological conditions, so the unqualified claim that insulin potentiation is the major effect of incretins overstates the source. (LLM, conf=0.83)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Liraglutide induced resolution of NASH in 39% of patients versus 9% of placebo.”
§ Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH > 2. Physiological Effects of Incretin Hormones > 2.2. Incretin Effects on Liver Enzymes, Steatosis, Inflammation and Fibrosis
What the sources say
- Supportedcites [103] Armstrong, 2016, Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study, Lancet source
The Results report resolution of definite NASH without worsening of fibrosis in 9 of 23 patients receiving liraglutide (39%). The Findings section reports 2 of 22 patients receiving placebo (9%) reached the same endpoint. (LLM, conf=0.95)
plainstates a causen = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several studies have shown an improvement in hepatic glucose and lipid metabolism after GLP-1 injection [167,168] or GLP-1RA treatment [24,102,169,170,171] either in humans and animal studies.”
§ Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH > 2. Physiological Effects of Incretin Hormones > 2.3. Effect of GLP-1 and GLP-1RA on Hepatic Glucose and Lipid Metabolism
What the sources say
- Not checked yetcites [167] Prigeon, 2003, Suppression of glucose production by GLP-1 independent of islet hormones: A novel extrapancreatic effect, Am. J. Physiol. Endocrinol. Metab. source
- Not checked yetcites [168] Seghieri, 2013, Direct effect of GLP-1 infusion on endogenous glucose production in humans, Diabetologia source
- Not checked yetcites [24] Gastaldelli, 2016, Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study, Hepatology source
- Supportedcites [102] Armstrong, 2016, Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis, J. Hepatol. source
The Discussion reports that liraglutide, a GLP-1 analogue, enhanced hepatic insulin sensitivity and decreased hepatic lipogenesis in patients with NASH. The Introduction also describes animal studies showing improvements in hepatic steatosis and glucose production after GLP-1 therapy. This supports the claim’s GLP-1RA-treatment component; the citation is not attached to the separate GLP-1-injection component. (LLM, conf=0.93)
- Partly supportedcites [169] Gupta, 2012, The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis, Am. J. Pathol. sourceExperimental — accuracy not yet measured
In “Ex4 Decreases Fat Content and Causes Lipid Droplet Fission” (page not given), the paper reports reduced liver triglycerides and lipid-droplet fission after Exendin 4 treatment in steatotic mice. This supports the hepatic lipid-metabolism part of the claim, but the paper does not report improved hepatic glucose metabolism or a treatment result in humans. (LLM, conf=0.88)
- Not checked yetcites [170] Saccomanno, 2011, Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis, Liver Int. Off. J. Int. Assoc. Study Liver
- Not checked yetcites [171] Cersosimo, 2011, Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects, J. Clin. Endocrinol. Metab. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
114 more claims · 27 with their cited sources checked
Create a free account to see all 220 claims and to verify the 202 references still open.
- It may state two separate claims as one. 93
- Probably not a substantial claim. 11
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1RAs have a positive effect on postprandial TAG and lipoprotein metabolism (mainly VLDL), with a reduction in TAG concentrations in the postprandial state due to the reduction in VLDL assembly and secretion42,128,129 but also an action on chylomicron assembly and clearance.[128], [129], [130], [131]”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH > 2. Physiological Effects of Incretin Hormones > 2.1. Incretin Secretion and Physiological Effects
“GIP is also an incretin hormone but its power to stimulate insulin secretion was considered minor compared to GLP-1 [20].”
§ Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH > 2. Physiological Effects of Incretin Hormones > 2.1. Incretin Secretion and Physiological Effects
“The early studies by Nauck and Holst have shown that the actions of GLP-1 and GIP on insulin secretion are nearly equal and additive in healthy humans [20,21]”
Citations
Cites
Items 201–311 of 311
Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats
Zhang, Q., Xiao, X., Li, M., Yu, M., Ping, F., Zheng, J., Wang, T., & Wang, X. (2017) · PLOS ONE · doi:10.1371/journal.pone.0184735 · Cited by 124
Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis
Zhou, M., Yang, H., Learned, R. M., Tian, H., & Ling, L. (2017) · Nature Communications · doi:10.1038/ncomms15433 · Cited by 123
Parker, V. E. R., Robertson, D., Wang, T., Hornigold, D. C., Petrone, M., Cooper, A. T., Posch, M. G., Heise, T., Plum-Moerschel, L., Schlichthaar, H., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz047 · Cited by 123
Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease
Fan, H., Pan, Q., Xu, Y., & Yang, X. (2013) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302013000900005 · Cited by 122
Degirolamo, C., Modica, S., Vacca, M., Di Tullio, G., Morgano, A., D'Orazio, A., Kannisto, K., Parini, P., & Moschetta, A. (2015) · Hepatology · doi:10.1002/hep.27274 · Cited by 121
Firneisz, G., Varga, T., Lengyel, G., Fehér, J., Ghyczy, D., Wichmann, B., Selmeci, L., Tulassay, Z., Rácz, K., & Somogyi, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012226 · Cited by 121
How Inflammation Impinges on NAFLD: A Role for Kupffer Cells
Duarte, N., Coelho, I. C., Patarrão, R. S., Almeida, J. I., Penha-Gonçalves, C., & Macedo, M. P. (2015) · BioMed Research International · doi:10.1155/2015/984578 · Cited by 120
Self-citationStefan, N., Ramsauer, M., Jordan, P., Nowotny, B., Kantartzis, K., Machann, J., Hwang, J., Nowotny, P., KAHL, S., Harreiter, J., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70170-0 · Cited by 120
Liu, L., Yan, H., Xia, M., Zhao, L., Lv, M., Zhao, N., Rao, S., Yao, X., Wu, W., Pan, B., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3292 · Cited by 118
Role of aramchol in steatohepatitis and fibrosis in mice
Iruarrizaga‐Lejarreta, M., Varela‐Rey, M., Fernández‐Ramos, D., Martínez‐Arranz, I., Delgado, T. C., Simon, J., Gutiérrez‐de Juan, V., delaCruz‐Villar, L., Azkargorta, M., Lavin, J. L., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1107 · Cited by 113
Gut hormone polyagonists for the treatment of type 2 diabetes
Brandt, S. J., Götz, A., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.021 · Cited by 111
Yan, X., Feng, B., Li, P., Tang, Z., & Wang, L. (2016) · Journal of Diabetes Research · doi:10.1155/2016/2093171 · Cited by 110
Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease
Reilly, N. R., Lebwohl, B., Hultcrantz, R., Green, P. H. R., & Ludvigsson, J. F. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.01.013 · Cited by 110
Samson, S. L., Sathyanarayana, P., Jogi, M., Gonzalez, E. V., Gutierrez, A., Krishnamurthy, R., Muthupillai, R., Chan, L., & Bajaj, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2317-z · Cited by 110
Boubia, B., Poupardin, O., Barth, M., Binet, J., Peralba, P., Mounier, L., Jacquier, E., Gauthier, E., Lepais, V., Chatar, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01285 · Cited by 110
Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice
Mentzel, S., Dijkman, H. B., Van Son, J. P., Koene, R. A., & Assmann, K. J. (1996) · Journal of Histochemistry & Cytochemistry · doi:10.1177/44.5.8627002 · Cited by 108
Jall, S., Sachs, S., Clemmensen, C., Finan, B., Neff, F., DiMarchi, R. D., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.02.002 · Cited by 107
Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: A case series
Kenny, P. R., Brady, D. E., Torres, D. M., Ragozzino, L., Chalasani, N., & Harrison, S. A. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.363 · Cited by 106
Sumida, Y., Murotani, K., Saito, M., Tamasawa, A., Osonoi, Y., Yoneda, M., & Osonoi, T. (2019) · Hepatology Research · doi:10.1111/hepr.13236 · Cited by 106
Inoue, M., Hayashi, A., Taguchi, T., Arai, R., Sasaki, S., Takano, K., Inoue, Y., & Shichiri, M. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.12980 · Cited by 105
Lee, Y.-H., Kim, J. H., Kim, S. R., Jin, H. Y., Rhee, E.-J., Cho, Y. M., & Lee, B.-W. (2017) · Journal of Korean Medical Science · doi:10.3346/jkms.2017.32.1.60 · Cited by 104 · cited 1×
“Lobeglitazone PPAR γ PO Phase III Yes No NA NA Yes [77]”
BackgroundDeFronzo, R. A., Triplitt, C., Qu, Y., Lewis, M. S., Maggs, D., & Glass, L. C. (2010) · Diabetes Care · doi:10.2337/dc09-1521 · Cited by 104
Mulvihill, E. E., Varin, E. M., Gladanac, B., Campbell, J. E., Ussher, J. R., Baggio, L. L., Yusta, B., Ayala, J., Burmeister, M. A., Matthews, D., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.007 · Cited by 102
Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15
Zhou, M., Luo, J., Chen, M., Yang, H., Learned, R. M., DePaoli, A. M., Tian, H., & Ling, L. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.027 · Cited by 102
Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36
Iepsen, E. W., Lundgren, J., Holst, J. J., Madsbad, S., & Torekov, S. S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1116 · Cited by 101
Featured article: Structure moderation of gut microbiota in liraglutide-treated diabetic male rats
Zhang, Q., Xiao, X., Zheng, J., Li, M., Yu, M., Ping, F., Wang, T., & Wang, X. (2018) · Experimental Biology and Medicine · doi:10.1177/1535370217743765 · Cited by 101
Valdecantos, M. P., Pardo, V., Ruiz, L., Castro‐Sánchez, L., Lanzón, B., Fernández‐Millán, E., García‐Monzón, C., Arroba, A. I., González‐Rodríguez, Á., Escrivá, F., et al. (2017) · Hepatology · doi:10.1002/hep.28962 · Cited by 100
Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease
Fuchs, C., Traussnigg, S., & Trauner, M. (2016) · Seminars in Liver Disease · doi:10.1055/s-0036-1571296 · Cited by 100
Khoo, J., Hsiang, J., Taneja, R., Law, N., & Ang, T. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13007 · Cited by 99
Fuchs, M., & Sanyal, A. J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.05.019 · Cited by 97
HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH
De Minicis, S., Agostinelli, L., Rychlicki, C., Sorice, G. P., Saccomanno, S., Candelaresi, C., Giaccari, A., Trozzi, L., Pierantonelli, I., Mingarelli, E., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097136 · Cited by 97
Self-citationParlevliet, E. T., Wang, Y., Geerling, J. J., Schröder-Van der Elst, J. P., Picha, K., O'Neil, K., Stojanovic-Susulic, V., Ort, T., Havekes, L. M., Romijn, J. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049152 · Cited by 97
Gastaldelli, A., Gaggini, M., Daniele, G., Ciociaro, D., Cersosimo, E., Tripathy, D., Triplitt, C., Fox, P., Musi, N., DeFronzo, R., et al. (2016) · Hepatology · doi:10.1002/hep.28827 · Cited by 96
Self-citationSearching for coeliac disease in patients with non-alcoholic fatty liver disease
Bardella, M. T., Valenti, L., Pagliari, C., Peracchi, M., Farè, M., Fracanzani, A. L., & Fargion, S. (2004) · Digestive and Liver Disease · doi:10.1016/j.dld.2004.01.012 · Cited by 92
Zhou, Z.-Y., Ren, L.-W., Zhan, P., Yang, H.-Y., Chai, D.-D., & Yu, Z.-W. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.21 · Cited by 92
Seghieri, M., Christensen, A. S., Andersen, A., Solini, A., Knop, F. K., & Vilsbøll, T. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00649 · Cited by 92
Seko, Y., Sumida, Y., Tanaka, S., Mori, K., Taketani, H., Ishiba, H., Hara, T., Okajima, A., Umemura, A., Nishikawa, T., et al. (2017) · Hepatology Research · doi:10.1111/hepr.12834 · Cited by 90
Seko, Y., Sumida, Y., Tanaka, S., Mori, K., Taketani, H., Ishiba, H., Hara, T., Okajima, A., Umemura, A., Nishikawa, T., et al. (2017) · Hepatology Research · doi:10.1111/hepr.12837 · Cited by 89
Cusi, K., Sattar, N., García‐Pérez, L. ‐., Pavo, I., Yu, M., Robertson, K. E., Karanikas, C. A., & Haupt, A. (2018) · Diabetic Medicine · doi:10.1111/dme.13697 · Cited by 89
Han, E., Lee, Y., Lee, B., Kang, E. S., & Soo, B. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010259 · Cited by 88
Cheng, C., Tan, J., Qian, W., Zhang, L., & Hou, X. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.08.017 · Cited by 86
Regulation of free fatty acid metabolism by glucagon
Carlson, M. G. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.77.1.11 · Cited by 85
Ohki, T., Isogawa, A., Toda, N., & Tagawa, K. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0383-1 · Cited by 83
Sturgeon, C., Lan, J., & Fasano, A. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13343 · Cited by 82
Pierantonelli, I., Rychlicki, C., Agostinelli, L., Giordano, D. M., Gaggini, M., Fraumene, C., Saponaro, C., Manghina, V., Sartini, L., Mingarelli, E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11744-6 · Cited by 82
Self-citationGastaldelli, A., Repetto, E., Guja, C., Hardy, E., Han, J., Jabbour, S. A., & Ferrannini, E. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13907 · Cited by 82
Self-citationHe, Y., Haynes, W., Meyers, C. D., Amer, A., Zhang, Y., Mahling, P., Mendonza, A. E., Ma, S., Chutkow, W., & Bachman, E. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13654 · Cited by 81
DePaoli, A. M., Higgins, L. S., Henry, R. R., Mantzoros, C., & Dunn, F. L. (2014) · Diabetes Care · doi:10.2337/dc13-2480 · Cited by 79
Seko, Y., Nishikawa, T., Umemura, A., Yamaguchi, K., Moriguchi, M., Yasui, K., Kimura, M., Iijima, H., Hashimoto, T., Sumida, Y., et al. (2018) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s184767 · Cited by 79
Rinella, M. E., Trotter, J. F., Abdelmalek, M. F., Paredes, A. H., Connelly, M. A., Jaros, M. J., Ling, L., Rossi, S. J., DePaoli, A. M., & Harrison, S. A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.11.032 · Cited by 79
McCaughan, G. W., Gorrell, M. D., Bishop, G. A., Abbott, C. A., Shackel, N. A., McGuinness, P. H., Levy, M. T., Sharland, A. F., Bowen, D. G., Yu, D., et al. (2000) · Immunological Reviews · doi:10.1034/j.1600-0528.2002.017420.x · Cited by 78
Bedossa, P., Tordjman, J., Aron-Wisnewsky, J., Poitou, C., Oppert, J.-M., Torcivia, A., Bouillot, J.-L., Paradis, V., Ratziu, V., & Clément, K. (2017) · Gut · doi:10.1136/gutjnl-2016-312238 · Cited by 78 · cited 1×
“The real prevalence of the disease is unknown, but it increases up to 57% in those with body mass index (BMI) of 30kg/m2 or greater (obesity), to 70% in diabetic subjects, and 90% in morbidly obese patients undergoing metabolic surgery [2,3].”
BackgroundGraziani, F., Talocco, C., de Sire, R., Petito, V., Lopetuso, L. R., Gervasoni, J., Persichilli, S., Franceschi, F., Ojetti, V., Gasbarrini, A., et al. (2019) · PubMed · doi:10.26355/eurrev_201901_16894 · Cited by 78
Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study
Itani, T., & Ishihara, T. (2018) · Obesity Science & Practice · doi:10.1002/osp4.294 · Cited by 77
Takase, T., Nakamura, A., Miyoshi, H., Yamamoto, C., & Atsumi, T. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej16-0295 · Cited by 76
Bi, Y., Zhang, B., Xu, W., Yang, H., Feng, W., Li, C., Tong, G., Li, M., Wang, X., Shen, S., et al. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0638-3 · Cited by 75
Schmitt, C., Portron, A., Jadidi, S., Sarkar, N., & DiMarchi, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13024 · Cited by 74
Olivares, M., Schüppel, V., Hassan, A. M., Beaumont, M., Neyrinck, A. M., Bindels, L. B., Benítez-Páez, A., Sanz, Y., Haller, D., Holzer, P., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01900 · Cited by 72
Dong, Y., Lv, Q., Li, S., Wu, Y., Li, L., Li, J., Zhang, F., Sun, X., & Tong, N. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.11.009 · Cited by 71
The Regulation of Peripheral Metabolism by Gut-Derived Hormones
Sun, E. W. L., Martin, A. M., Young, R. L., & Keating, D. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00754 · Cited by 71 · cited 2×
“The intestinal cells sec et sev r l hormones—among these glucagon-like peptide-1 (GLP-1), g ucose-d pendent insulinotropic pep ide (GIP), xyntomodulin and possibly glucago —that are involved with pancreatic h rmones insulin and glucagon and are important for the maintenance of glucose and lipid home st sis [6].”
BackgroundWirth, R., Bódi, N., Maróti, G., Bagyánszki, M., Talapka, P., Fekete, É., Bagi, Z., & Kovács, K. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110440 · Cited by 69
DePaoli, A. M., Zhou, M., Kaplan, D. D., Hunt, S. C., Adams, T. D., Learned, R. M., Tian, H., & Ling, L. (2019) · Diabetes · doi:10.2337/db18-1305 · Cited by 66
GLP‐1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c‐JNK
Zhang, L., Yang, M., Ren, H., Hu, H., Boden, G., Li, L., & Yang, G. (2013) · Liver International · doi:10.1111/liv.12120 · Cited by 65
Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Stemmer, K. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12837 · Cited by 65
Grimm, M., Han, J., Weaver, C., Griffin, P., Schulteis, C. T., Dong, H., & Malloy, J. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2660 · Cited by 63
Daniele, G., Iozzo, P., Molina-Carrion, M., Lancaster, J., Ciociaro, D., Cersosimo, E., Tripathy, D., Triplitt, C., Fox, P., Musi, N., et al. (2015) · Diabetes · doi:10.2337/db14-1718 · Cited by 62 · cited 1×
“GLP-1 also has other pleiotropic effects (Figure 1), including delay in gastric emptying and glucose absorption [24,25], stimulation of brain areas involved in the regulation of glucose homeostasis and food reward [26], suppression of glucagon secretion [25], beneficial effects on cardiovascular risk factors, a natriu…”
BackgroundSelf-citationThe effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities
Day, A., Feher, M. D., Chopra, R., & Mayne, P. (1993) · Metabolism · doi:10.1016/0026-0495(93)90056-t · Cited by 61
Suzuki, D., Toyoda, M., Kimura, M., Miyauchi, M., Yamamoto, N., Sato, H., Tanaka, E., Kuriyama, Y., Miyatake, H., Abe, M., et al. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.8961 · Cited by 61
Metformin Improves Ileal Epithelial Barrier Function in Interleukin-10 Deficient Mice
Xue, Y., Zhang, H., Sun, X., & Zhu, M.-J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0168670 · Cited by 61
Ida, S., Kaneko, R., & Murata, K. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0845-x · Cited by 61 · cited 1×
“Pemafibrate PPAR α/SPPARM PO Phase II NA NA Yes NA Yes [48]”
BackgroundGupta, N. A., Kolachala, V. L., Jiang, R., Abramowsky, C., Romero, R., Fifadara, N., Anania, F., Knechtle, S., & Kirk, A. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.07.015 · Cited by 60
Gluud, L. L., Knop, F. K., & Vilsbøll, T. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005325 · Cited by 59
Souto, K. P., Meinhardt, N. G., Ramos, M. J., Kulczynski, J. M. U., Stein, A. T., & Damin, D. C. (2017) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.09.527 · Cited by 59
Ohta, A., Kato, H., Ishii, S., Sasaki, Y., Nakamura, Y., Nakagawa, T., Nagai, Y., & Tanaka, Y. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1363888 · Cited by 56
Acton, J. J., Akiyama, T. E., Chang, C. H., Colwell, L. F., Debenham, S. D., Doebber, T. W., Einstein, M., Liu, K., McCann, M. E., Moller, D. E., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900097m · Cited by 55
Samson, S. L., Gonzalez, E. V., Yechoor, V., Bajaj, M., Oka, K., & Chan, L. (2008) · Molecular Therapy · doi:10.1038/mt.2008.198 · Cited by 54
Lucas, K. J., Lopez, P., Lawitz, E., Sheikh, A. M., Aizenberg, D., Hsia, S. H., Goh, B. B. G., Vierling, J. M., Frias, J., White, J., et al. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.12.129 · Cited by 51
Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects
Cersosimo, E., Gastaldelli, A., Cervera, A., Wajcberg, E., Sriwijilkamol, A., Fernandez, M., Zuo, P., Petz, R., Triplitt, C., Musi, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2146 · Cited by 50
Self-citationHeise, T., Morrow, L., Hompesch, M., Häring, H., Kapitza, C., Abt, M., Ramsauer, M., Magnone, M. C., & Fuerst‐Recktenwald, S. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12317 · Cited by 50
MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis
Colca, J. R., McDonald, W. G., & Adams, W. J. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1494153 · Cited by 49
Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
Miyake, T., Yoshida, S., Furukawa, S., Sakai, T., Tada, F., Senba, H., Yamamoto, S., Koizumi, Y., Yoshida, O., Hirooka, M., et al. (2018) · Open Medicine · doi:10.1515/med-2018-0059 · Cited by 48
Intra-islet glucagon-like peptide 1
Fava, G. E., Dong, E. W., & Wu, H. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.05.016 · Cited by 45 · cited 1×
“Some studies showed that pancreatic alpha cells may also secrete GLP-1 [13].”
BackgroundComparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease
Yaghoubi, M., Jafari, S., Sajedi, B., Gohari, S., Akbarieh, S., Heydari, A. H., & Jameshoorani, M. (2017) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000981 · Cited by 45
Lee, P. C. H., Gu, Y., Yeung, M. Y., Fong, C. H. Y., Woo, Y. C., Chow, W. S., Tan, K., & Lam, K. S. L. (2018) · Diabetes Therapy · doi:10.1007/s13300-017-0355-3 · Cited by 44
Li, B., Wang, Y., Ye, Z., Yang, H., Cui, X., Wang, Z., & Liu, L. (2018) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps29831 · Cited by 43
Karhapää, P., Uusitupa, M. I. J., Voutilainen, E., & Laakso, M. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.200 · Cited by 39
Zhou, M., Learned, R. M., Rossi, S. J., Tian, H., DePaoli, A. M., & Ling, L. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m089961 · Cited by 38
Patel, V., Joharapurkar, A., Kshirsagar, S., Sutariya, B., Patel, M., Patel, H., Pandey, D., Patel, D., Ranvir, R., Kadam, S., et al. (2018) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/1871525716666180118152158 · Cited by 37
Bando, Y., Ogawa, A., Ishikura, K., Kanehara, H., Hisada, A., Notumata, K., Okafuji, K., & Toya, D. (2017) · Diabetology International · doi:10.1007/s13340-016-0302-y · Cited by 35
The Human Gut Microbiome in Liver Diseases
Davis, B., & Bajaj, J. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1602763 · Cited by 34
Gao, J.-H., Wen, S., Tong, H., Wang, C.-H., Yang, W.-J., Tang, S.-H., Yan, Z.-P., Tai, Y., Ye, C., Liu, R., et al. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00428.2015 · Cited by 33
Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance
Whyte, M. B., Shojaee-Moradie, F., Sharaf, S. E., Jackson, N. C., Fielding, B., Hovorka, R., Mendis, J., Russell-Jones, D., & Umpleby, A. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01176 · Cited by 32
Bergenstal, R. M., Li, Y., Porter, T. K. B., Weaver, C., & Han, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12026 · Cited by 31
Watanabe, T., Tamura, Y., Kakehi, S., Funayama, T., Gastaldelli, A., Takeno, K., Kawaguchi, M., Yamamoto, R., Sato, F., Ikeda, S., et al. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12262 · Cited by 31
Self-citationKikuchi, M., Fukuyama, K., & Epstein, W. L. (1988) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(88)90268-8 · Cited by 30 · cited 1×
“DPP-4 is a 110 kilodaltons (kDa) membrane-associated peptidase that is expressed on the apical surface of epithelial and acinar cells, endothelial cells, fibroblasts, and lymphocytes [8–10] and also exists as a soluble circulating form in plasma [11].”
BackgroundDEPAOLI, A., PHUNG, V., BASHIR, M. R., MORROW, L., BEYSEN, C., YAN, A., LING, L., BAXTER, B., LUSKEY, K. L., & OLEFSKY, J. M. (2019) · Diabetes · doi:10.2337/db19-140-lb · Cited by 28
Liu, J., Tarasenko, L., Terra, S. G., Huyck, S., Wu, L., Pong, A., Calle, R. A., Gallo, S., Darekar, A., & Mancuso, J. P. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164119842513 · Cited by 25
Camastra, S., Astiarraga, B., Tura, A., Frascerra, S., Ciociaro, D., Mari, A., Gastaldelli, A., & Ferrannini, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12836 · Cited by 23
Self-citationYokote, K., Sano, M., Tsumiyama, I., & Keefe, D. L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14006 · Cited by 23
CHOI, I. Y., KIM, J. K., LEE, J. S., PARK, E., KIM, Y. H., JUNG, S. Y., & KIM, S. J. (2018) · Diabetes · doi:10.2337/db18-1106-p · Cited by 18
Calle, R. A., Bergman, A. J., Somayaji, V. R., Chidsey, K., & Kazierad, D. J. (2019) · Journal of Hepatology · doi:10.1016/s0618-8278(19)30122-7 · Cited by 18
Blaslov, K., Zibar, K., Bulum, T., & Duvnjak, L. S. (2013) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2013.10.013 · Cited by 14
Ozaki, A., Yoneda, M., Kessoku, T., Iwaki, M., Kobayashi, T., Honda, Y., Ogawa, Y., Imajo, K., Sakai, E., Taguri, M., et al. (2019) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2019.100516 · Cited by 13
Duarte, N., Coelho, I., Holovanchuk, D., Almeida, J. I., Penha‐Gonçalves, C., & Macedo, M. P. (2018) · Hepatology Communications · doi:10.1002/hep4.1225 · Cited by 10
Self-citationChoi, J., Kim, J. K., LEE, S. M., et al. (2020) · Diabetes · doi:10.2337/db20-1830-p · Cited by 10
Choi, J. D., Baek, S. J., KIM, Y., Eun, K., Kwon, S. C., Morrow, L., Hompesch, M., & Kang, J. (2019) · Diabetes · doi:10.2337/db19-982-p · Cited by 9
Seo, D., Faintuch, B. L., Aparecida de Oliveira, E., & Faintuch, J. (2017) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2017.03.002 · Cited by 8
Rosenstock, M., Ayalon, M., Mansbach, H., Liu, Y., & Margalit, M. (2019) · Journal of Hepatology · doi:10.1016/s0618-8278(19)30274-9 · Cited by 7
Roy, S., & Ghosh, A. (2019) · Cureus · doi:10.7759/cureus.6361 · Cited by 6
DePaoli, A. M., Bashir, M. R., Phung, V., et al. (2019) · Journal of Hepatology · doi:10.1016/s0618-8278(19)30120-3 · Cited by 3
Skarbaliene, J., Madsen, A. N., Mouritzen, U., et al. (2017) · Journal of Hepatology · doi:10.1016/s0168-8278(17)30466-x · Cited by 3
Research works printed but not linked: 2
- You, 2016, Long-Acting GLP-1 and Glucagon Receptor Dual Agonists for the Treatment of Type 2 Diabetes, Diabetes, 65, A221
- Hershkovitz, O., Bar-IIan, A., Hart, G., and Fima, E. (2013, January 15–18). The long-acting dual GLP-1/Glucagon Agonist, MOD-6030 improves glycaemic control and induces a prolonged weight loss in diet induced obesity mice following a once weekly administration. Proceedings of the Endocrine Society’s 95th Annual Meeting and Expo, San Francisco, CA, USA.
Cited by
Gut liver brain axis in diseases: the implications for therapeutic interventions
Yan, M., Man, S., Sun, B., Ma, L., Guo, L., Huang, L., & Gao, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01673-4 · Cited by 287
“78 79,80 However, the impact of SCFAs is controversial.”
BackgroundChehrehgosha, H., Sohrabi, M. R., Ismail-Beigi, F., Malek, M., Reza Babaei, M., Zamani, F., Ajdarkosh, H., Khoonsari, M., Fallah, A. E., & Khamseh, M. E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01011-3 · Cited by 173
“However, despite the role of incretin hormones in NAFLD pathogenesis [17] and various interventions targeting the gut-pancreas-liver axis, in NASH treatment no approved treatment is currently available [17, 18].”
BackgroundLipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
Self-citationLu, S.-C., Chen, M., Atangan, L., Killion, E. A., Komorowski, R., Cheng, Y., Netirojjanakul, C., Falsey, J. R., Stolina, M., Dwyer, D., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100263 · Cited by 91
“This increase correlated with a rebound effect on BW and food intake, a phenomenon observed earlier with long-acting GLP-1Ra.46 Hepatic and adipose lipogenesis are inhibited with GLP-1.”
BackgroundActivation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
Xu, G.-X., Wei, S., Yu, C., Zhao, S.-Q., Yang, W.-J., Feng, Y.-H., Pan, C., Yang, K.-X., & Ma, Y. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1199519 · Cited by 88
“Some researchers have proposed the concept of the Gut-PancreasLiver Axis to enhance the understanding of the relevant mechanism (Svegliati-Baroni et al., 2020).”
Background
Metadata
- Authors
- Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A.
- Affiliations
- Liver Injury and Transplant Unit, Ospedali Riuniti Ancona, 60020 Ancona, Italy
- Scuola Superiore Sant'Anna (IT)
- Marche Polytechnic University (IT)
- Associacao Protectora dos Diabeticos de Portugal (PT)
- Corresponding author
- Macedo, Maria Paula
- Gastaldelli, Amalia
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-08-13
- Volume
- 21
- Issue
- 16
- Pages
- 5820
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7461212
- OpenAlex
- W3048942363
- Semantic Scholar
- 793a99829ad1a6f81b3791803ec3f1470665d924
- Cited by
- 66
- References
- 333
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 12 · 2023: 12 · 2022: 14 · 2021: 13
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion, cc-by)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- H2020 Marie Skłodowska-Curie Actions (722619, 734719)
- Consiglio Nazionale delle Ricerche (B54I19000370005)
- Fundação para a Ciência e a Tecnologia (PTDC/BIM-MET/2115/2014, PTDC/MEC-MET/29314/2017)
- iNOVA4Health (UID/Multi/04462/2013)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, gut-liver axis, incretins, gut microbiota, metagenomics, metabolomics, intestinal barrier dysfunction, bacterial translocation, NAFLD pathogenesis, NAFLD treatment
- MeSH terms
- Gastrointestinal Microbiome, Animals, Humans, Liver, Pancreas, Gastrointestinal Tract, Incretins, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.